Abstract
Tramadol is commonly prescribed for pain control because it presents a lower risk for addiction and respiratory depression compared to other opioids. However, tramadol's serotonin and norepinephrine reuptake inhibitory effects result in a unique adverse effect profile. Two such adverse events are serotonin syndrome and seizures. The prevalence of tramadol-induced serotonin syndrome and seizures is modest in the general population, but if left untreated, the morbidity and mortality can be high; therefore, prompt recognition and management is essential. Various risk factors such as medical comorbidities, use or abuse of supratherapeutic doses of tramadol, and concomitant administration of proconvulsant serotonergic cytochrome P-450 inhibitors will help clinicians identify individuals at an elevated risk for serotonin toxicity and seizures. Serotonin syndrome and seizures can be effectively treated by administering benzodiazepines, providing supportive care, and discontinuing tramadol and other contributing agents. Cyproheptadine should be administered in moderate to severe cases of serotonin syndrome. Our objective is to summarize the literature on the pharmacology, epidemiology, risk factors, clinical presentations, and evidence...Continue Reading
Citations
Jan 25, 2019·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Brian Patrick MurrayZiad Kazzi
Mar 13, 2019·JAMA : the Journal of the American Medical Association·Chao ZengYuqing Zhang
Oct 30, 2019·Food & Function·Youyou LuLanwei Zhang
Jul 3, 2019·Journal of Addictive Diseases·Momtaz Ahmed AbdelWahabReham Abdel Maqsoud
Feb 6, 2020·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Jie WeiYuqing Zhang
Jan 7, 2020·International Anesthesiology Clinics·C James WatsonMichael Ganetsky
Oct 28, 2019·Medical Care·Molly M JefferyEllen Meara
May 20, 2020·The Journal of Pharmacy and Pharmacology·Mi JinChenxiang Wang
Oct 2, 2019·Journal of Addiction Medicine·Dale Terasaki, Kaylin Klie
Aug 8, 2019·Current Pain and Headache Reports·Luisa M BigalStephanie Dunbar
Aug 28, 2020·Journal of Psychopharmacology·Ahmad A AltarifiS Stevens Negus
Aug 17, 2019·Pharmacoepidemiology and Drug Safety·Cecilia P ChungWayne A Ray
Aug 14, 2019·Clinical Nurse Specialist CNS·Patricia Anne O'Malley
Aug 11, 2020·Expert Opinion on Pharmacotherapy·Nebojsa Nick KnezevicIvana Knezevic
Oct 6, 2020·Journal of Pain & Palliative Care Pharmacotherapy·Nikhil MohanRabia S Atayee
Jan 21, 2021·Expert Opinion on Pharmacotherapy·Kevin S Tang, Ankur D Shah
Oct 20, 2019·Osteoarthritis and Cartilage·J WeiY Zhang
Feb 17, 2021·The Journal of the American Academy of Orthopaedic Surgeons·Chukwuweike U GwamJohannes F Plate
Mar 14, 2021·Clinical Drug Investigation·Matthew P RutmanRichard G Stefanacci
Sep 16, 2020·International Journal of Surgery Case Reports·Yijun LiuQulian Guo
Dec 22, 2020·ACS Pharmacology & Translational Science·John A Bumpus
Nov 16, 2018·La Revue de médecine interne·D VodovarB Mégarbane
Apr 20, 2021·Social Science & Medicine·Sandrine GalloisGintare Pranskaityté
Jun 24, 2021·Drugs & Aging·Ye-Jin KangSun-Young Jung
Sep 28, 2021·Toxicological Sciences : an Official Journal of the Society of Toxicology·Y IshibashiI Suzuki
Nov 17, 2021·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Keijiro KannoSeiji Ohtori